Cargando…
Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells
Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (m...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036162/ https://www.ncbi.nlm.nih.gov/pubmed/35480140 http://dx.doi.org/10.1155/2022/4404406 |
_version_ | 1784693463664558080 |
---|---|
author | Wan, Renping Liao, Hongliang Liu, Jingting Zhou, Lin Yin, Yingqiu Mu, Tianhao Wei, Jie |
author_facet | Wan, Renping Liao, Hongliang Liu, Jingting Zhou, Lin Yin, Yingqiu Mu, Tianhao Wei, Jie |
author_sort | Wan, Renping |
collection | PubMed |
description | Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (mRNAsi) of LUAD patients' data in TCGA. Association analysis of mRNAsi was performed with clinical features, somatic mutation, and tumor immunity. A prognostic prediction model was established with LASSO Cox regression. Kaplan-Meier Plotter (KM-plotter) and time-dependent ROC were applied to assess signature performance. For LUAD, univariate and multivariate Cox analysis was performed to identify independent prognostic factors. LUAD tissues showed a noticeably higher mRNAsi in than nontumor tissues, and it showed significant differences in T, N, M, AJCC stages, and smoking history. The most frequently mutated gene was TP53, with a higher mRNAsi relating to more frequent mutation of TP53. The mRNAsi was significantly negatively correlated with immune score, stromal score, and ESTIMATE score in LUAD. The blue module was associated with mRNAsi. The 5-gene signature was confirmed as an independent indicator of LUAD prognosis that could promote personalized treatment of LUAD and accurately predict overall survival (OS) of LUAD patients. |
format | Online Article Text |
id | pubmed-9036162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90361622022-04-26 Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells Wan, Renping Liao, Hongliang Liu, Jingting Zhou, Lin Yin, Yingqiu Mu, Tianhao Wei, Jie Biomed Res Int Research Article Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (mRNAsi) of LUAD patients' data in TCGA. Association analysis of mRNAsi was performed with clinical features, somatic mutation, and tumor immunity. A prognostic prediction model was established with LASSO Cox regression. Kaplan-Meier Plotter (KM-plotter) and time-dependent ROC were applied to assess signature performance. For LUAD, univariate and multivariate Cox analysis was performed to identify independent prognostic factors. LUAD tissues showed a noticeably higher mRNAsi in than nontumor tissues, and it showed significant differences in T, N, M, AJCC stages, and smoking history. The most frequently mutated gene was TP53, with a higher mRNAsi relating to more frequent mutation of TP53. The mRNAsi was significantly negatively correlated with immune score, stromal score, and ESTIMATE score in LUAD. The blue module was associated with mRNAsi. The 5-gene signature was confirmed as an independent indicator of LUAD prognosis that could promote personalized treatment of LUAD and accurately predict overall survival (OS) of LUAD patients. Hindawi 2022-04-16 /pmc/articles/PMC9036162/ /pubmed/35480140 http://dx.doi.org/10.1155/2022/4404406 Text en Copyright © 2022 Renping Wan et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wan, Renping Liao, Hongliang Liu, Jingting Zhou, Lin Yin, Yingqiu Mu, Tianhao Wei, Jie Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells |
title | Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells |
title_full | Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells |
title_fullStr | Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells |
title_full_unstemmed | Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells |
title_short | Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells |
title_sort | development of a 5-gene signature to evaluate lung adenocarcinoma prognosis based on the features of cancer stem cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036162/ https://www.ncbi.nlm.nih.gov/pubmed/35480140 http://dx.doi.org/10.1155/2022/4404406 |
work_keys_str_mv | AT wanrenping developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells AT liaohongliang developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells AT liujingting developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells AT zhoulin developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells AT yinyingqiu developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells AT mutianhao developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells AT weijie developmentofa5genesignaturetoevaluatelungadenocarcinomaprognosisbasedonthefeaturesofcancerstemcells |